# To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

> **NCT00397956** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (—)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** MK0826, ertapenem sodium / Duration of Treatment: 14 Days

## Key facts

- **NCT ID:** NCT00397956
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397956, "To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00397956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*